Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: EXEL
  • CUSIP: 30161Q10
Key Metrics:
  • Previous Close: $21.74
  • 50 Day Moving Average: $19.59
  • 200 Day Moving Average: $15.06
  • 52-Week Range: $3.55 - $23.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 241.00
  • P/E Growth: 2.18
  • Market Cap: $6.27B
  • Outstanding Shares: 286,455,000
  • Beta: 1.78
Profitability:
  • Net Margins: -123.81%
  • Return on Assets: -30.16%
Debt:
  • Debt-to-Equity Ratio: 2.54%
  • Current Ratio: 2.09%
  • Quick Ratio: 2.07%
Additional Links:
Companies Related to Exelixis:

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.11 (34.93% downside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetDetails
1/28/2017William BlairReiterated RatingOutperformView Rating Details
1/24/2017Cowen and CompanyReiterated RatingOutperformView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$17.00View Rating Details
10/10/2016Piper Jaffray CompaniesUpgradeNeutral -> OverweightView Rating Details
10/7/2016Leerink SwannReiterated RatingPositive$15.00View Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57View Rating Details
9/15/2016Stifel NicolausBoost Price TargetBuy$12.00 -> $15.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Exelixis (NASDAQ:EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017Q416($0.01)$64.88 millionListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exelixis (NASDAQ:EXEL)
Current Year EPS Consensus Estimate: $-0.44 EPS
Next Year EPS Consensus Estimate: $0.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.27)($0.24)($0.26)
Q2 20162($0.29)($0.28)($0.29)
Q3 20162($0.12)($0.07)($0.10)
Q4 20162($0.01)($0.01)($0.01)
Q1 20172$0.00$0.00$0.00
Q2 20172($0.01)$0.00($0.01)
Q3 20172$0.01$0.04$0.03
Q4 20172$0.04$0.07$0.06
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Exelixis (NASDAQ:EXEL)
Insider Ownership Percentage: 5.90%
Institutional Ownership Percentage: 78.40%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Exelixis (NASDAQ:EXEL)
DateHeadline
finance.yahoo.com logoWhy Earnings Season Could Be Great for Exelixis (EXEL) (NASDAQ:EXEL)
finance.yahoo.com - February 24 at 11:30 AM
News IconForward Earnings Estimate of Exelixis, Inc.(EXEL) - Highland Mirror (NASDAQ:EXEL)
www.highlandmirror.com - February 23 at 5:05 PM
News IconTaking a Look at the Data Behind Exelixis, Inc. (EXEL) - StockNewsJournal (NASDAQ:EXEL)
stocknewsjournal.com - February 23 at 5:05 PM
finance.yahoo.com logoACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time? (NASDAQ:EXEL)
finance.yahoo.com - February 23 at 5:05 PM
News IconAnalyst's Proposition on Exelixis, Inc. (EXEL), Synergy Pharmaceuticals Inc. (SGYP) - The USA Commerce (NASDAQ:EXEL)
theusacommerce.com - February 22 at 5:22 PM
nasdaq.com logoIntercept (ICPT) to Post Q4 Earnings: What's in the Cards? (NASDAQ:EXEL)
www.nasdaq.com - February 22 at 8:55 AM
reuters.com logoBRIEF-Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab (NASDAQ:EXEL)
www.reuters.com - February 18 at 4:47 PM
tmcnet.com logoExelixis Announces Phase 1 Trial Results for Cabozantinib … (NASDAQ:EXEL)
www.tmcnet.com - February 18 at 4:47 PM
us.rd.yahoo.com logoExelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors (NASDAQ:EXEL)
us.rd.yahoo.com - February 18 at 4:47 PM
us.rd.yahoo.com logo5:05 pm Exelixis presented Ph 1 trial results for cabozantinib in combination with nivolumab in refractory metastatic urothelial carcinoma and other tumors; has 'encouraging tolerability, safety and activity profile' (NASDAQ:EXEL)
us.rd.yahoo.com - February 18 at 4:47 PM
News IconAnalytical Guide for Exelixis, Inc. (EXEL), New Residential Investment Corp. (NRZ) Stakeholders - The USA Commerce (NASDAQ:EXEL)
www.theusacommerce.com - February 18 at 6:07 AM
businesswire.com logoExelixis Announces Phase 1 Trial Results for Cabozantinib in ... - Business Wire (press release) (NASDAQ:EXEL)
www.businesswire.com - February 18 at 6:07 AM
News IconThe Must-Know Technicals As They Stand For Exelixis, Inc. (EXEL) - NY Stock News (NASDAQ:EXEL)
nystocknews.com - February 17 at 3:19 PM
News Icon1globe Capital Llc. Picked Up Exelixis Inc. (NASDAQ:EXEL) Shares - Small Cap Exclusive (press release) (NASDAQ:EXEL)
smallcapexclusive.com - February 17 at 3:19 PM
News IconAre Analysts Optimistic About Where Exelixis, Inc. (NASDAQ:EXEL) is Heading? - Winfield Review (NASDAQ:EXEL)
winfieldreview.com - February 17 at 3:19 PM
News IconWhat Is Going On With Exelixis, Inc. (NASDAQ:EXEL)? - FinancialsTrend (NASDAQ:EXEL)
www.financialstrend.com - February 17 at 3:19 PM
finance.yahoo.com logoEasier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis (NASDAQ:EXEL)
finance.yahoo.com - February 17 at 3:19 PM
finance.yahoo.com logoRadius Health (RDUS) Q4 Earnings: Will the Stock Disappoint? (NASDAQ:EXEL)
finance.yahoo.com - February 17 at 3:19 PM
News IconExelixis Inc EXEL Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:EXEL)
www.bioportfolio.com - February 16 at 5:03 PM
News IconACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Exelixis, Inc. (NASDAQ:EXEL) (NASDAQ:EXEL)
mundoaguaysaneamiento.net - February 16 at 5:03 PM
fool.com logoBetter Buy: Exelixis, Inc. vs. Bristol-Myers Squibb (NASDAQ:EXEL)
www.fool.com - February 13 at 5:52 PM
News IconExelixis, Inc. (NASDAQ:EXEL) Goes Past The Average Analyst Yearly Target Price Of $20.50 Per Share (NASDAQ:EXEL)
www.financialstrend.com - February 13 at 9:32 AM
News IconTaking a Look at the Chart for Exelixis, Inc. (EXEL) - The USA Commerce (NASDAQ:EXEL)
theusacommerce.com - February 10 at 10:40 PM
News IconExelixis, Inc. (EXEL): From Top to Bottom - StockNewsJournal (NASDAQ:EXEL)
stocknewsjournal.com - February 10 at 5:37 PM
News IconLookout for Price Target? Mattel, Inc. (MAT), Exelixis, Inc. (EXEL) - StockNewsJournal (NASDAQ:EXEL)
stocknewsjournal.com - February 10 at 5:37 PM
zacks.com logoExelixis (EXEL) Shares March Higher, Can It Continue? (NASDAQ:EXEL)
www.zacks.com - February 10 at 3:46 AM
us.rd.yahoo.com logoBuy 4 Stocks Riding High on Superb Earnings Acceleration (NASDAQ:EXEL)
us.rd.yahoo.com - February 9 at 5:41 PM
News IconThe Technical Case for and Against Exelixis, Inc. (EXEL) - The USA Commerce (NASDAQ:EXEL)
theusacommerce.com - February 9 at 3:38 AM
News IconWhy Investors remained confident on MGIC Investment Corporation (MTG), Exelixis, Inc. (EXEL)? - StockNewsJournal (NASDAQ:EXEL)
stocknewsjournal.com - February 9 at 3:38 AM
fool.com logo3 Scorching Hot Biotech Stocks -- Are They Buys? (NASDAQ:EXEL)
www.fool.com - February 8 at 4:53 PM
forbes.com logoExelixis Reaches Analyst Target Price (NASDAQ:EXEL)
www.forbes.com - February 8 at 10:25 AM
finance.yahoo.com logoExelixis to Present at the Leerink Partners Global Healthcare Conference on February 15 (NASDAQ:EXEL)
finance.yahoo.com - February 7 at 6:19 PM
News IconWhat Analysts are Predicting For Exelixis, Inc. (EXEL), Computer Sciences Corporation (CSC)? - The USA Commerce (NASDAQ:EXEL)
www.theusacommerce.com - February 6 at 10:12 PM
businesswire.com logoExelixis to Release Fourth Quarter and Full Year 2016 Financial ... - Business Wire (press release) (NASDAQ:EXEL)
www.businesswire.com - February 3 at 10:31 PM
fool.com logo2 Big Reasons Exelixis, Inc. Soared 22% in January -- The Motley Fool - Motley Fool (NASDAQ:EXEL)
www.fool.com - February 3 at 10:31 PM
thestreet.com logoHopes for Tax Reform, Less Regulation Lift Indices (NASDAQ:EXEL)
realmoney.thestreet.com - February 3 at 5:29 PM
us.rd.yahoo.com logoExelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:EXEL)
us.rd.yahoo.com - February 2 at 5:37 PM
finance.yahoo.com logoExelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017 (NASDAQ:EXEL)
finance.yahoo.com - February 2 at 5:37 PM
fool.com logo2 Big Reasons Exelixis, Inc. Soared 22% in January (NASDAQ:EXEL)
www.fool.com - February 2 at 7:42 AM
News IconEarnings Forecast Research on Exelixis, Inc. (EXEL) - Highland Mirror (NASDAQ:EXEL)
www.highlandmirror.com - February 1 at 10:41 PM
News IconExelixis, Inc. (NASDAQ:EXEL) Broker Price Targets For The Coming Week (NASDAQ:EXEL)
viveremilano.biz - February 1 at 5:41 PM
News IconExelixis, Inc. (NASDAQ:EXEL) Quarterly EPS Projection At $-0.01 - Stock Observer (NASDAQ:EXEL)
www.thestockobserver.com - February 1 at 4:21 AM
News IconExelixis and Takeda Enter into Exclusive Licensing Agreement (NASDAQ:EXEL)
www.finchannel.com - January 31 at 5:48 PM
4-traders.com logoEXELIXIS, INC. : Entry into a Material Definitive Agreement (form 8-K) (NASDAQ:EXEL)
www.4-traders.com - January 31 at 5:48 PM
investopedia.com logoExelixis, Takeda Ink $145M Cancer License Pact (EXEL) (NASDAQ:EXEL)
www.investopedia.com - January 31 at 5:48 PM
us.rd.yahoo.com logoExelixis Inks Partnership with Takeda for Cabometyx in Japan (NASDAQ:EXEL)
us.rd.yahoo.com - January 31 at 5:48 PM
us.rd.yahoo.com logoExelixis, Takeda Sign Japanese Cancer Drug Deal (NASDAQ:EXEL)
us.rd.yahoo.com - January 31 at 5:48 PM
smarteranalyst.com logoStock Update (NASDAQ:EXEL): Exelixis, Inc. and Takeda Enter into Exclusive ... (NASDAQ:EXEL)
www.smarteranalyst.com - January 30 at 11:18 PM
finance.yahoo.com logoExelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan (NASDAQ:EXEL)
au.finance.yahoo.com - January 30 at 11:18 PM
finance.yahoo.com logo6:02 pm Exelixis and Takeda (TKPYY (NASDAQ:EXEL)
finance.yahoo.com - January 30 at 11:18 PM

Social

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?

6 analysts have issued 1-year price targets for Exelixis' shares. Their forecasts range from $8.00 to $17.00. On average, they expect Exelixis' share price to reach $14.11 in the next twelve months.

When will Exelixis announce their earnings?

Exelixis is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in April. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters. Meanwhile, Cabometyx also received approval in the EU in September, which triggered a milestone payment of $60 million to Exelixis. The product will be marketed in the EU by Exelixis’ partner, Ipsen. Moreover, Exelixis is developing cabozantinib in a broad development program comprising over 45 clinical studies across multiple indications. Moreover, successful commercialization of the other marketed drug, Cotellic in the U.S. will boost the top line. Exelixis’ share price has outperformed the Zacks classified Biomedical and Genetics industry in the last one year driven by the approval of Cabometyx. However, expenses are expected to increase as the company continues the commercialization of the drug for newer indications." (2/6/2017)

  • Leerink Swann analysts commented, "We view today’s better than expected 2Q revenue preannouncement as a positive step as XENT works through some sales force restructuring/turnover related issues that have impacted the company since late-2015. The better than expected preliminary top- line results suggest business momentum is picking up. We continue to believe stock performance from here is tied to mgmt’s ability to hire new reps and drive higher sales force productivity. 2Q preliminary revenue of $19.3M ahead of consensus. XENT beat the Street/us by ~3%, which we think is a positive sign on mgmt’s ability to execute following a surprise in-line 1Q. We think expectations were for an in-line 2Q and are encouraged that some of the disruptions in 1Q may be in the rear-view mirror, and it appears that Propel Mini is beginning to generate positive momentum. The company also hired one rep more than what we were projecting (now have 73 territory managers vs. our 72 est) and rep productivity was slightly above our forecast ($1.10M/rep vs. $1.07M/rep est.)." (7/19/2016)

Who owns Exelixis stock?

Exelixis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.98%), State Street Corp (2.64%), Two Sigma Investments LP (1.59%), Janus Capital Management LLC (0.70%), Renaissance Technologies LLC (0.46%) and Bogle Investment Management L P DE (0.42%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, George A Scangos, Gisela Schwab, Lance Willsey and Peter Lamb.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Janus Capital Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, Oxford Asset Management, Castleark Management LLC, Graham Capital Management L.P. and Guggenheim Capital LLC. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, George A Scangos, Gisela Schwab and Peter Lamb.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Two Sigma Investments LP, Franklin Resources Inc., Alyeska Investment Group L.P., Russell Investments Group Ltd., Dimensional Fund Advisors LP, Nicholas Investment Partners LP and Allianz Asset Management AG.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Exelixis stock cost?

One share of Exelixis stock can currently be purchased for approximately $21.69.

Exelixis (NASDAQ:EXEL) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Earnings History Chart

Earnings by Quarter for Exelixis (NASDAQ:EXEL)

Dividend History Chart

Dividend Payments by Quarter for Exelixis (NASDAQ:EXEL)

Last Updated on 2/24/2017 by MarketBeat.com Staff